News briefing: Biogen gets a quick date with an FDA panel for controversial aducanumab; Abeona CEO, board members exit — shares implode
Mark your calendars for November 6, which looms as the next major test for Biogen’s aducanumab. That’s the day the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
